Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study

    January 2025 in “ Journal of Dermatological Treatment ”
    Carlo Alberto Vignoli, Luigi Gargiulo, Luciano Ibba, Anna Balato, Mauro Barbareschi, Stefania Barruscotti, Giulia Bazzacco, Francesco Bellinato, Vittoria Giulia Bianchi, Valeria Boccaletti, Raffaele D. Caposiena Caro, Silvia Mariel Ferrucci, Alessandro Fraghì, Elisabetta Fulgione, Giuseppe Gallo, Paolo Gisondi, Isotta Giunipero di Corteranzo, Piergiorgio Malagoli, Angelo Valerio Marzano, Santo Raffaele Mercuri, Diego Orsini, Pietro Quaglino, Simone Ribero, Antonio Costanzo, Alessandra Narcisi
    This 52-week multicenter retrospective study evaluated the long-term effectiveness and safety of baricitinib, a JAK 1/2 inhibitor, in treating severe alopecia areata (AA) in a real-world setting. Involving 96 adult patients from 11 Italian Dermatology Units, the study found that 61.5% of patients achieved a SALT score ≤ 20, indicating significant hair regrowth. Additionally, 67.6% and 69.7% of patients showed marked improvement in eyebrow and eyelash hair loss, respectively. No significant adverse safety events were reported, confirming baricitinib's effectiveness and safety as a treatment for severe AA, consistent with clinical trial results.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results